Editorial: Metals in cancer: from intracellular signaling to therapy

Katia Aquilano,Giuseppe Filomeni,Raffaella Faraonio,Anastasia De Luca

DOI: https://doi.org/10.3389/fonc.2024.1495825

IF: 4.7

2024-10-11

Frontiers in Oncology

Abstract:cancer spread (2). Recently, the intricate interplay between these two metal-dependent cell death pathways has been further explored (3)(4). Bian et al. provide a comprehensive review of the role of intracellular copper bioavailability in cancer onset and development, emphasizing the interconnec4on between cuproptosis and ferroptosis, and discuss the ongoing clinical trials on copper-based chemotherapeu4c strategies. The authors considered the evolu4on of the clinical use of copper chelators and ionophores (molecules capable of increasing intracellular copper concentra4on), highligh4ng one of the main limita4ons of these therapeu4c approaches. In fact, the systemic administra4on of these molecules is likely to result in adverse side effects. For this reason, current research is focusing on iden4fying drug delivery systems specifically targe4ng the tumor mass.Dysregula4on of zinc (5), selenium (6), and magnesium (7) homeostasis has also been implicated in cancer onset and progression. Similarly, it is well established that an intracellular excess of heavy metals (e.g., lead, mercury, and chromium) can induce tumorigenesis. Heavy metal intoxica4on is also involved in the development of several neurological disorders and the ac4va4on of cellular senescence, as observed in these neurological pathologies (8). Pamphle= and Bishop, through elemental biomapping of various 4ssues, are able to measure a range of heavy metals including inorganic mercury, silver, bismuth, cadmium, lead, and nickel in several 4ssue samples from kidney, pancreas, thyroid, nervous system, breast and anterior pituitary. Their study on 170 autopsies from pa4ents with hypertension, pancrea4c cancer, breast cancer, gliomas, mul4ple sclerosis, neurodegenera4ve disorders (i.e., Parkinson's disease, age-related macular degenera4on), and from aged pa4ents, reveals that aging cells accumula4ng heavy metals are more likely to undergo malignant transforma4on. In par4cular, they find an age-dependent accumula4on of mercury in cell popula4ons such as renal tubule cells in the kidney, b-cells in the pancreas, follicle epithelium in the thyroid. In the nervous system, mercury and silver accumula4on is mainly observed in the locus ceruleus and in the hypophysis. Addi4onally, they observe increased concentra4ons of mercury in pancrea4c and breast cancer 4ssues, reinforcing the no4on that toxic metal accumula4on during aging contributes to tumorigenesis, and sugges4ng that reducing environmental contamina4on by heavy metals could mi4gate cancer incidence.These findings have strongly promoted and supported the synthesis and development of metal-based chemotherapeu4c strategies to exploit their an4tumor proper4es. In par4cular, several of copper-and iron-based compounds have been proposed to increase the intracellular bioavailability of these trace metals in cancer cells, thereby triggering cuproptosis or ferroptosis. In this regard, pla4num-based compounds (i.e., carbopla4n, oxalipla4n, and cispla4n) remain among the most commonly used drugs for the treatment of various cancers, such as lung, ovarian, cervical, tes4cular, bladder, and colorectal cancer. However, over the last decade, researchers have also focused on iden4fying nature-derived bioac4ve compounds capable of hindering cancer through the induc4on of non-canonical cell death signaling pathways (9) or func4oning as adjuvants to standard cancer therapies. In their original paper, Yang et al. demonstrate the synergic ac4vity of the lignan Schisandrin C (SC) and cispla4num in a mouse model of breast and colon cancer. This polyphenol acts by increasing the cispla4n-induced ac4va4on of type I interferon (IFN) signaling, leading to improved an4tumor immune responses. Specifically, they provide evidence that SC increases the type I IFN cascade mediated by the innate immunity cyclic GMP-AMP synthase (cGAS)-s4mulator of interferon genes (STING) pathway. Addi4onally, SC enhances the recruitment of T lymphocytes and NK cells in the tumor site. The simultaneous administra4on of SC and cispla4n not only significantly improves overall survival (OS) compared to cispla4n alone but also increases cispla4n tolerability, limi4ng weight loss in tumor-bearing mice.In an alterna4ve approach, Wang and colleagues propose a cispla4n-independent treatment for non-oncogene-addicted advanced non-small cell lung cancer (NSCLC). Their mul4center retrospec4ve study, enrolling 87 pa4ents who were unresponsive to first-line pla4num-based doublet chemotherapy, demonstrates that the treatment with the S-1 molecule, composed of tegafur (FT), gimeracil (CDHP), and oteracil potassium (OXO), significantly improves progression-free survival (PFS) and overall survival (OS), with beaer tolerability in NSCLC pa4ents compared to pla4num-based regimens, thus suppor4ng its poten4al use as a second-line of interven4on in cancer treatment.Overall, the studies featured in this issue underscore th -Abstract Truncated-

oncology